ReviewMolecular medicine reports2026
Multifaceted regulatory role of proline‑ and glutamine-rich splicing factor in tumors (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proline‑ and glutamine‑rich splicing factor (SFPQ) is an RNA‑binding protein that is predominantly localized in the nucleus and plays a multifaceted regulatory role in the process of gene expression. The functions of SFPQ include the promotion or inhibition of gene transcription, pre‑mRNA splicing, mRNA processing, transport and localization, and translation. The primary impact of SFPQ on cellular processes is the regulation of cell cycle progression and apoptosis. In addition, SFPQ represents an important element of paraspeckles, exerting a notable influence on gene expression within the nucleus. The expression of SFPQ is altered in tumors, promoting the development and drug resistance of tumors in various ways, notably altering the prognosis of patients. In the present review, the fundamental physiological functions of SFPQ and its particular effects on tumorigenesis and development are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.